×
About 485 results

ALLMedicine™ Acute Graft Versus Host Disease Center

Research & Reviews  146 results

Teniposide-intensified hematopoietic stem cell transplantation with acute graft versus ...
https://doi.org/10.21037/apm-21-3122
Annals of Palliative Medicine; Wang WJ, Cheng HY et. al.

Dec 8th, 2021 - Teniposide, as a more potent inhibitor of topoisomerase II compared with etoposide, shows less damage on hematopoietic stem cells. Few data are available on teniposide in hematopoietic stem cell transplantation (HSCT) for high-risk or refractory r...

ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
https://clinicaltrials.gov/ct2/show/NCT04006652

Dec 7th, 2021 - Finding a donor remains a challenge for patients in need of an urgent hematopoietic stem cell transplantation (HSCT). The ability to obtain half matched stem cells from any family member represents a significant breakthrough in the field. Haploide...

Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease
https://clinicaltrials.gov/ct2/show/NCT05121142

Nov 16th, 2021 - While hematopoietic stem cell transplant (HSCT) is an effective therapy, graft versus host disease (GVHD) is the most significant complication after HSCT. Both acute GVHD and chronic GVHD are leading causes of non-relapse morbidity and mortality. ...

Image Guided Volumetrically Modulated Total Body Irradiation (TBI): Progress on Single ...
https://doi.org/10.1016/j.ijrobp.2021.07.967
International Journal of Radiation Oncology, Biology, Phy... Teruel JR, Galavis P et. al.

Oct 28th, 2021 - TBI is a backbone of many conditioning regimens for hematopoietic stem cell transplants but can lead to both acute and late toxicity including radiation-induced interstitial pneumonitis. The incidence of idiopathic pneumonia syndrome (IPS) after T...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  38 results

ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
https://clinicaltrials.gov/ct2/show/NCT04006652

Dec 7th, 2021 - Finding a donor remains a challenge for patients in need of an urgent hematopoietic stem cell transplantation (HSCT). The ability to obtain half matched stem cells from any family member represents a significant breakthrough in the field. Haploide...

Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease
https://clinicaltrials.gov/ct2/show/NCT05121142

Nov 16th, 2021 - While hematopoietic stem cell transplant (HSCT) is an effective therapy, graft versus host disease (GVHD) is the most significant complication after HSCT. Both acute GVHD and chronic GVHD are leading causes of non-relapse morbidity and mortality. ...

Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation
https://clinicaltrials.gov/ct2/show/NCT03529825

Oct 12th, 2021 - This study is for patients who will be having a blood/marrow transplant (BMT) to treat leukemia, lymphoma or other cancer of the blood. The blood or marrow cells will come from another person (donor)-allogeneic BMT. Bacterial infections and acute ...

Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft
https://clinicaltrials.gov/ct2/show/NCT03887156

Sep 28th, 2021 - Acute Graft Versus Host Disease (aGVHD) is the most frequent complication in allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). It affects up to 50% patients, among whom 15% to 25% develop severe forms, often lethal, yet impossible to...

Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease
https://clinicaltrials.gov/ct2/show/NCT05047328

Sep 17th, 2021 - Despite improvements in allogeneic hematopoietic stem cell transplantation (allo-HSCT) settings, graft-versus-host disease (GvHD) remains a significant issue after transplantation and a major cause of non-relapse mortality. Acute GvHD (aGvHD) stil...

see more →

News  8 results

An Overview of the Graft vs Host Disease Landscape
https://www.onclive.com/view/an-overview-of-the-graft-vs-host-disease-landscape

Nov 15th, 2021 - Transcript: Corey Cutler, MD, MPH, FRCPC: The most important part is really understanding what the diseases that we’re dealing with are. What is acute and chronic graft versus host disease [GVHD]? These are 2 distinct manifestations of alloimmuni...

Genomic Era Reaches Pediatric Oncology
https://www.onclive.com/view/genomic-era-reaches-pediatric-oncology

Dec 5th, 2020 - Rajen Mody, MBBS The relative rarity of pediatric cancers has hampered the work of uncovering their causes and developing new therapies, but efforts to expand the use of genomic and biomarker testing are beginning to provide new options for child...

FDA Grants Remestemcel-L Priority Review for Pediatric GVHD
https://www.onclive.com/view/fda-grants-remestemcell-priority-review-for-pediatric-gvhd

Dec 4th, 2020 - The FDA has granted remestemcel-L (Ryoncil) a priority review designation for the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD), according to Mesoblast Limited, the manufacturer of the allogeneic cell the...

FDA Grants ALPN-101 Orphan Drug Designations in GVHD
https://www.onclive.com/view/fda-grants-alpn101-orphan-drug-designations-in-gvhd

Dec 4th, 2020 - The FDA has granted 2 Orphan Drug Designations to ALPN-101 for the prevention and treatment of acute graft-versus-host-disease (GVHD), according to Alpine Immune Sciences, Inc., the company developing the first-in-class selective dual T cell costi...

Ruxolitinib/Etanercept Combo Resolves Steroid-Refractory Acute GVHD Following Allogeneic SCT
https://www.onclive.com/view/ruxolitinibetanercept-combo-resolves-steroidrefractory-acute-gvhd-following-allogeneic-sct

Dec 4th, 2020 - A novel treatment of ruxolitinib (Jakafi) combined with etanercept (Enbrel) led to encouraging response and survival rates in patients who developed grades 3/4 steroid-resistant acute graft-versus-host disease (GVHD) after undergoing allogeneic st...

see more →

Patient Education  1 results see all →